SCHEMBL8277671

SCHEMBL8277671

CC(C)Cc1ccc(C(N)=O)cc1Nc1nc2c(ccc3ccncc32)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.38
AR P10275 1/20 0.35
DYRK1A Q13627 2/20 0.34
HRH4 Q9H3N8 1/20 0.34
PARP14 Q460N5 3/20 0.34
TNIK Q9UKE5 1/20 0.34
PIM1 P11309 2/20 0.33
MAPK14 Q16539 1/20 0.33
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33
RET P07949 1/20 0.33
FGFR1 P11362 1/20 0.33
PRKACA P17612 1/20 0.33
FLT1 P17948 1/20 0.33
LTK P29376 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8277672 0.93 XIAP (0.38) XIAPARDYRK1AHRH4PARP14
SCHEMBL8278680 0.84 XIAP (0.39) XIAPARDYRK1APARP14TNIK
SCHEMBL8277670 0.83 TNIK (0.39) XIAPARDYRK1AHRH4TNIK
SCHEMBL8277560 0.82 SYK (0.37) XIAPARDYRK1APARP14MAPK14
SCHEMBL6118093 0.80 HRH4 (0.38) DYRK1AHRH4PARP14TNIKMAPK14
SCHEMBL8277561 0.80 DYRK1A (0.35) XIAPARDYRK1AHRH4PARP14
SCHEMBL8277609 0.79 DYRK1A (0.35) XIAPDYRK1AHRH4PARP14MAPK14
SCHEMBL8277535 0.79 DYRK1A (0.35) XIAPDYRK1AHRH4PARP14MAPK14
SCHEMBL8277556 0.78 DYRK1A (0.34) DYRK1AHRH4PARP14MAPK14
SCHEMBL8277543 0.78 DYRK1A (0.34) XIAPDYRK1AHRH4PARP14MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129811-A1 TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129811-A1 TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP3, MMP13 XIAP 965/4885AR 4023/4885DYRK1A 4569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.